A first in human clinical trial of NXL-001
Latest Information Update: 20 Sep 2021
At a glance
- Drugs NXL-001 (Primary)
- Indications Stroke
- Focus Adverse reactions; First in man
- 20 Sep 2021 New trial record
- 13 Sep 2021 According to a NeuExcell Therapeutics media release, FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement for NXL-001. FUJIFILM Diosynth Biotechnologies will manufacture NXL-001.